UnitedHealth’s Disappointing Quarter and Conservative Forecasts
UnitedHealth recently reported lower-than-expected revenue for the second quarter and has adopted a cautious stance regarding its 2025 revenue predictions. The company revealed that rising medical costs have exceeded their previous expectations, which will likely continue to impact financial performance.
Despite this setback, UnitedHealth anticipates a return to revenue growth by 2026. The adjusted revenue for 2025 is projected to be at least $16 per share, a significant drop from the earlier expectation of as much as $30 per share.
According to analysts from Factset, a full-year profit is forecasted at $20.64 per share. UnitedHealth Group Inc. is a major player in health insurance and pharmacy benefit management in the U.S., based in Eden Prairie, Minnesota, and also operates Optum, which focuses on care and technology services.
In May, the company had to retract its 2025 forecast due to unexpected healthcare costs and the abrupt departure of CEO Andrew Witty, who was succeeded by Chairman Stephen Hemsley. Hemsley had previously led the company for over ten years until 2017.
This followed an unusual move in April when the company lowered its forecasts, leading to a substantial decline in stock value, marking the worst single-day performance for UnitedHealth in over twenty-five years.
In June, Hemsley committed to providing a clearer revenue outlook for 2025 in conjunction with the second-quarter results, admitting to underestimating trends in care and costs, though he also indicated that improvements are being pursued.
For the second quarter, UnitedHealth recorded adjusted earnings of $4.08 per share against gross revenue of $111.6 billion. Analysts had expected revenue of $111.5 billion and earnings per share of $4.48, as per Factset. Even though revenue rose by 13%, profits fell 19% to $3.41 billion, largely due to a 20% increase in healthcare expenses, which totaled $78.6 billion.
Typically, UnitedHealth is the first insurer to report quarterly revenue, but this summer it reduced annual forecasts and issued disappointing results, similar to its competitors Elevance Health Inc. and Centene Corp.
Many insurance companies are currently facing unexpectedly rapid increases in medical costs, which have been driven by more expensive emergency room visits and rising prescription drug prices, especially for cancer treatments and gene therapies. Additionally, there has been growth in behavioral health services addressing mental health and substance use disorders.
On Tuesday, UnitedHealth’s shares dropped to $272.30, reflecting a roughly 3% decline before the market opened. This comes after reaching an all-time high of over $630 last November. Since then, the stock has largely experienced a downward trend, especially following the tragic death of CEO Brian Thompson.
So far this year, the stock has decreased by 44%, while the Dow Jones Industrial Average, of which UnitedHealth is a component, has risen by 5%.
